Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphoma.

Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphoma.

Rituximab is the first line drug to treat non Hodgkin's lymphoma (B-NHL) alone or in combination with chemotherapy. However, 30-40% of B-NHL patients are unresponsive to rituximab or resistant after therapy. Human phosphatidylethanolamine-binding protein 4 (hPEBP4) is a novel member of PEBP fam...

Full description

Bibliographic Details
Main Authors: Kai Wang, Yu Jiang, Weiyan Zheng, Zhiyong Liu, Hui Li, Jianzhou Lou, Meidi Gu, Xiaojian Wang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3581549?pdf=render

Internet

http://europepmc.org/articles/PMC3581549?pdf=render

Similar Items